Transdermal Allergy Immunotherapy Study Shows Promise As An Alternative to Injections

VIEW PEER-REVIEWED JOURNAL

Final results from the RELIEF Study Released

Topical Analgesics Reduce Opioid Usage over 3 and 6-months

VIEW PEER-REVIEWED JOURNAL

“Traditional Allergy Immunotherapy consists of multiple years of Injections (sub-cutaneous immunotherapy- (SCIT)). We now have preliminary evidence that supplying allergens through topical administration shows a decrease in IgE levels and may prove to be a viable alternative to allergy shots and the millions of people who are allergy sufferers. We are conducting more clinical trials and excited to expand on these initial results.”

Peter Hurwitz
President, Clarity Science LLC
Co-Author

“The data from our recent studies showed that there are alternative pain management treatment options available for healthcare professionals to help address a patient’s pain. These options may lead to a reduced focus on Opioid prescribing and other oral analgesics and their side effects and have a significant and positive impact on patient care and outcomes.”

Peter Hurwitz
President, Clarity Science LLC

See informative results from our studies.

Current Scar Study

TARGET

(TopicAl Silicone in RestorinG Scars and Burn Tissue Evaluating Therapy)

Positive interim TARGET Results have been presented at leading conferences, including the 7th Joint Meeting of the European Tissue Repair Society & the Wound Healing Society held in Copenhagen, Denmark, among others.

ETRS Wound-Healing-Society-Logo-BW

Results from an interim analysis of our TARGET study (a scar and burn treatment study) show that adults using a prescribed topical scar and burn cream reported:

Size
Reduced scar/burn size as measured by clinicians and as perceived by patients.
Itch
Reduced itching.
Mood
Reduced scar/burn interference with general activity, mood, sleep, and life enjoyment.
Pain_Meds
Reduced pain medication use.

VIEW TARGET POSTER SEE TARGET STUDY DETAILS

Closed Pain Study

OPERA

(Optimizing Patient Experience and Response to Topical Analgesics)

Positive interim OPERA Results have been presented at important conferences, including the 4th Annual International Conference on Opioids held at Harvard Medical School, among others.

Opioidsharvard medical school
ACRPharvard medical school

Results from an interim analysis of our OPERA study (a pain study) show that patients with musculoskeletal and neuropathic pain using a prescribed topical analgesic reported:

Pain_Severity
Reduced pain severity for patients with neuropathic and musculoskeletal pain.
Daily_Activity
Reduced pain interference with general activity, mood, sleep, and life enjoyment.
Arthritis
Reduced number of primary pain complaints for arthritis, neuropathy, or radiculopathy.
OTC_Meds
Reduced use of over-the-counter medications, anti-inflammatory medications, and opioid analgesics.

VIEW OPERA POSTER SEE OPERA STUDY DETAILS

Conference & Publications Highlights

MORE CONFERENCES & PUBLICATIONS

News & Announcements

VISIT OUR NEWS PAGE